The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Comparing responders and non-responders for the loss of function NOD2 mutations
Megan Babette Barnet, MD, The Kinghorn Cancer Centre, Darlinghurst, Australia, summarizes the findings of a trial where whole genome sequencing was used on prospectively recruited patients with lung cancer. Exceptional responders, who did not reach progression-free survival (PFS) and had an immune-related adverse event, were compared with non-responders. Within the exceptional responder’s cohort, 40 patients had established loss of function mutation in NOD2, compared with non-responders where this figure was significantly lower. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
